UT Southwestern Harold C. Simmons Comprehensive Cancer Center | Strategic Alliance Partners

November 17, 2022

Praveen Ramakrishnan, MD, MS, discusses the evolving landscape of CAR T-cell therapy in diffuse large B-cell lymphoma.

November 07, 2022

Farrukh Awan, MD, discusses the current use of BTK inhibitors in the management of chronic lymphocytic leukemia and important factors to consider when determining the best treatment strategy.

November 04, 2022

Praveen Ramakrishnan, MD, MS, discusses the clinical implications of CAR T-cell therapy in large B-cell lymphoma.

November 03, 2022

Praveen Ramakrishnan, MD, discusses the negative results from the phase 3 BELINDA trial and its effect on the use of CAR T-cell products in aggressive B-cell non-Hodgkin lymphoma.

October 20, 2022

Farrukh Awan, MD, discusses new agents under investigation in chronic lymphocytic leukemia and mantle cell lymphoma and emphasizes the importance of weighing each drug’s risks and benefits against individual patient needs and preferences to make informed decisions.

October 18, 2022

Farrukh Awan, MD, discusses the evolution of treating frontline chronic lymphocytic leukemia.

October 18, 2022

Farrukh Awan, MD, discusses transplant and chemotherapy options in frontline diffuse large B-cell lymphoma, the emergence of CAR T-cell therapy in relapsed diffuse large B-cell lymphoma, and available targeted therapies in acute myeloid leukemia.

October 17, 2022

Praveen Ramakrishnan, MD, MS, discusses the evolution of diffuse large B-cell lymphoma treatment, the implications of key phase 3 studies, and how emerging bispecific T-cell engagers and antibody-drug conjugates may increase treatment accessibility beyond the limitations of CAR T-cell therapy for patients at various disease stages.

October 17, 2022

Sheena Bhalla, MD, discusses the need for improved understanding of EGFR exon 20 insertion mutations in the development of non–small cell lung cancer treatment.

October 05, 2022

Neil Desai, MD, discusses the investigation of immune checkpoint inhibitors with chemoradiation in urothelial cancer.

August 25, 2022

Although the efficacy of targeted agents and outcomes for patients with genetic mutations can vary, the availability of these treatments adds to the need for genetic testing across all patients with non–small cell lung cancer.

August 24, 2022

Neil Desai, MD, discusses the ideal patient for bladder preservation in urothelial cancer.

August 24, 2022

Neil Desai, MD, discusses the evolving standard of care in urothelial cancer.

July 13, 2022

Neil Desai, MD, discusses the variety of options available for patients with localized urothelial cancer who are ineligible for cisplatin-based chemoradiation.

June 23, 2022

Tian Zhang, MD, discusses the benefits of multidisciplinary collaboration, how to select the best agents for each patient, and how treatments such as radiation in RCC and bladder-sparing chemoradiation in urothelial cancer fit into the overall treatment paradigms for these diseases.

June 16, 2022

June 02, 2022

For the 10th consecutive year, OncLive® is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.

June 01, 2022

Heather McArthur, MD, MPH, described how the data from DESTINY-Breast03 reshapes the treatment landscape and offers added benefit to patients with brain metastases.

May 06, 2022

Heather McArthur, MD, MPH, discusses the FDA approval of fam-trastuzumab deruxtecan-nxki for second-line treatment in HER2-positive metastatic breast cancer.

May 04, 2022

The investigational RNA interference therapy, ARO-HIF2, reduced levels of hypoxia inducible factor-2 alpha expression and had acceptable tolerability when used in patients with clear cell renal cell carcinoma, according to data from the phase 1b AROHIF21001 trial.